Skip to main content

Postpartum Haemorrhage

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pharmacosmos
PharmacosmosDenmark - Holbaek
1 program
1
Iron isomaltoside 1000Phase 31 trial
Active Trials
NCT01895218Completed200Est. Dec 2014
Haemonetics
HaemoneticsMA - Boston
1 program
1
Fibrinogen ConcentratePhase 2/31 trial
Active Trials
NCT01359878Completed249Est. Jul 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PharmacosmosIron isomaltoside 1000
HaemoneticsFibrinogen Concentrate

Clinical Trials (2)

Total enrollment: 449 patients across 2 trials

NCT01895218PharmacosmosIron isomaltoside 1000

Treatment of Women After Postpartum Haemorrhage

Start: Jun 2013Est. completion: Dec 2014200 patients
Phase 3Completed
NCT01359878HaemoneticsFibrinogen Concentrate

Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial

Start: May 2011Est. completion: Jul 2013249 patients
Phase 2/3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.